Magle Chemoswed Holding Ab (MAGLE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Magle Chemoswed Holding Ab (MAGLE) has a cash flow conversion efficiency ratio of -0.006x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.52 Million ≈ $-271.62K USD) by net assets (Skr395.84 Million ≈ $42.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Magle Chemoswed Holding Ab balance sheet independence to measure how much of total assets are equity-financed.
Magle Chemoswed Holding Ab - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Magle Chemoswed Holding Ab's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MAGLE operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Magle Chemoswed Holding Ab Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Magle Chemoswed Holding Ab ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gaming Realms plc
LSE:GMR
|
0.246x |
|
Borders & Southern Petroleum plc
LSE:BOR
|
-0.003x |
|
Handal Resources Bhd
KLSE:7253
|
0.099x |
|
Ten Lifestyle Group PLC
LSE:TENG
|
0.186x |
|
Altai Resources Inc.
V:ATI
|
-0.051x |
|
Imalliance SA
PA:MLIML
|
N/A |
|
Dragon Mountain Gold Ltd
AU:DMG
|
-0.204x |
|
Octopus Aim Vct Plc
LSE:OOA
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Magle Chemoswed Holding Ab (2017–2025)
The table below shows the annual cash flow conversion efficiency of Magle Chemoswed Holding Ab from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Magle Chemoswed Holding Ab market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr395.84 Million ≈ $42.60 Million |
Skr-31.93 Million ≈ $-3.44 Million |
-0.081x | -286.53% |
| 2024-12-31 | Skr560.60 Million ≈ $60.33 Million |
Skr-11.70 Million ≈ $-1.26 Million |
-0.021x | -121.54% |
| 2023-12-31 | Skr158.22 Million ≈ $17.03 Million |
Skr15.33 Million ≈ $1.65 Million |
0.097x | +14.08% |
| 2022-12-31 | Skr146.77 Million ≈ $15.79 Million |
Skr12.47 Million ≈ $1.34 Million |
0.085x | -54.73% |
| 2021-12-31 | Skr138.79 Million ≈ $14.94 Million |
Skr26.04 Million ≈ $2.80 Million |
0.188x | +492.89% |
| 2020-12-31 | Skr116.12 Million ≈ $12.50 Million |
Skr-5.54 Million ≈ $-596.73K |
-0.048x | +23.40% |
| 2019-12-31 | Skr113.66 Million ≈ $12.23 Million |
Skr-7.08 Million ≈ $-762.46K |
-0.062x | -128.56% |
| 2018-12-31 | Skr50.67 Million ≈ $5.45 Million |
Skr11.06 Million ≈ $1.19 Million |
0.218x | -65.21% |
| 2017-12-31 | Skr42.98 Million ≈ $4.63 Million |
Skr26.96 Million ≈ $2.90 Million |
0.627x | -- |
About Magle Chemoswed Holding Ab
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride… Read more